The triglyceride and cholesterol content of total, very-low-, intermediate-, low-, and high-density hipoproteins, and of apolipoproteins (apo) Al, All, B, CII, CIII, and E were determined in plasma from 107 patients with clinically wellcontrolled diabetes and from 66 age-and weight-matched healthy normal subjects. The diabetic patients were separated into two groups: those with insulin-dependent diabetes mellitus (lOOM, type 1, n = 24) and those with non-insulindependent diabetes melhitus (NIDDM, type 2, n = 83). The latter group contained two subgroups: those treated by diet (type 2d, n = 42) or by insulin (type 2i, n = 41). High-density lipoprotein cholesterol was increased in 10DM patients, and decreased in NIDDM patients relative to control subjects. Mean apo Al values in IDDM patients were higher than in their respective controls and in NIDDM patients. Concentrations of apo B, CIII, and E were higher in all diabetic patients than in the healthy controls, but those of apo CII did not differ statistically between diabetics and nondiabetics. Although total plasma cholesterol and triglyceride concentrations were apparently near normal values in patients with good glycemic control, we found a persistent increase of intermediatedensity lipoproteins (remnants) in all the diabetic groups studied. This factor may be related to the perceived increased cardiovascular risk in these individuals.
Lipoprotein abnormalities in diabetes mellitus are well established and might account for the increased frequency of arteriosclerotic vascular disease observed in these patients despite good glycemic control (1, 2). Some workers (3, 4) have attempted to distinguish the lipoprotein and lipid changes observed in type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) from those in type 2 diabetes (noninsulin-dependent diabetes mellitus, NIDDM). 2 Although there is general agreement that the concentration of highdensity lipoprotein (HDL) cholesterol is higher than normal in type 1, and normal or lower in type 2 diabetes, reported findings are inconsistent for low-density lipoprotein (LDL) cholesterol values (5-11) and little is known about changes in intermediate-density
lipoproteins (IDL) in this disease (12) . Reliable information about these particles may be especially important in view of their postulated atherogenicity (13).
Avogaro et a!. (14) suggested that the apolipoproteins, mainly ape AL and apo B, or the ratio of the two, may be better than cholesterol and triglyceride concentrations alone as predictive factors for the development of coronary heart disease. This may well be true in conditions not exacerbated by confounding factors such as diabetes in general and diabetic sub-types in particular. We present here an attempt to discriminate between clearly defined groups on the basis of their lipid proffies and of the apoproteins known to affect their concentrations in plasma.
Materials and Methods
Subjects. We recruited 107 well-controlled diabetic patients from a population of 450 diabetics regularly attending the Diabetes Clinic at the Hospital Joan XXIII (Tarragona). To carefully delineate the groups, we studied only male subjects. Other exclusion criteria were the use of thiazide diuretics, beta-blockers, or any other drug known to alter lipoprotein metabolism; clinical or laboratory evidence of renal or hepatic damage; and evidence of other metabolic disorders. Diabetic patients were assigned to two groups according to the criteria of the National Diabetes Data Group (15) and the World Health Organization (16): type 1 (n = 24) and type 2 (n = 83). From the latter, we formed two subgroups:type 2d, those treated with diet (n = 42) and type 2i, those treated with diet and insulin (n = 41); none of the patients had been treated with sulfonylureas in the previous six months. The type 2i group consisted of patients whose Cpeptide concentration in plasma exceeded 0.60 nmolIL 6 mm afterintravenous administration of 1 mg of glucagon (17) .
The patients were matched with male controls for age (± 5 years), weight (±5 kg), smoking habits, and alcohol consumption. Because of the tendency of type 2 patients towards overweight and the difference in age of onset with respect to type 1 patients, two matching control groups were necessary: group A (n = 24) for type 1 patients, and group B (n = 42) for patients with type 2 diabetes.
Analyses. The clinical status of the diabetic subjects was assessed, and body mass index (BM1) was calculated according to the formula BMI = weight (kg)/height2 (m). Blood was collected in EDTA (1 mg per milliliter of plasma) after an overnight fast, and the samples were centrifuged immediately at 4#{176}C to obtain the plasma.
One aliquot was stored at -30 #{176}C for subsequent batched turbidimetric measurement of ape AL, All, and B (Boehringer Mannheim, Marburg,
F.R.G.). Ape CII, CIII
, and E were measured by single radial immunodifi'usion plates (Daiichi Pure Chemicals, Tokyo, Japan). Previous results obtained in our laboratory indicate no interferences in these analyses after storage of specimens at -30 #{176}C for as long as three months.
Another aliquot was subjected to immediate analysis of glucose, cholesterol, and triglyceride in a Monarch 2000 centrifugal analyzer (IL SpA, Milan, Italy) by standard enzymatic procedures; glycated hemoglobin was assayed by microcolumn chromatography (Isolab Inc., Akron, OH). The same day, plasma was subjected to sequential preparative ultracentriftigation for lipoproteins (18) in a Kontron TF'T 
Results
The biometric and laboratory data of the groups are shown in Table 1 . Diet-and insulin-treated type 2 patients were very similar in terms of age and weight, but tended to be older and with a higher BMI than type 1 patients. Glycated hemoglobin proportions were similar in all groUps. The percentage of smokers (47% of subjects) and the alcohol intake (8.9 to 19.5 g/week) were comparable with that observed in the control group (48%, and 9.5 to 23 g/week, respectively).
3To convert substance concentration (mmol/L) to mass concentration (mgIL) the conversion factors are: cholesterol x 38.8, triglyceride x 88.0.
Within-group comparison of cholesterol and triglyceride concentrations in plasma and in the isolated lipoprotein classes showed that in the type 1 group of patients, there was a significant increase of IDL cholesterol (P <0.01), IDL triglyceride (P <0.01), and HDL cholesterol (P <0.05) relative to the control group A. Similarly, in the type 2 groups of patients, increased concentrations of IDL cholesterol (P <0.05, 2d vs control; andP <0.01, 2i vs control), and IDL triglyceride (P <0.05, 2d vs control; andP <0.001, 2i vs control) were observed. The concentrations of IDL cholesterol and IDL triglyceride of the type 2i group of patients significantly exceeded those of the type 2d group (P <0.05 and P <0.001, respectively).
Cross-group comparisons of cholesterol and triglyceride values showed that in type 1 patients the mean plasma cholesterol concentration was lower than that in the type 2i group (P <0.05), whereas the mean VLDL cholesterol, VLDL triglyceride, and IDL triglyceride concentrations were lower than those observed in both of the type 2 groups of patients (P <0.001,P <0.01, andP <0.001, respectively). Conversely, the mean HDL cholesterol concentration in type 1 patients was higher than that of type 2 patients, reaching statistical significance (P <0.05) relative to the type 2d group alone. exceeded that of the control subjects (P <0.05) and the two type 2 groups (2d, P <0.001; and 2i, P <0.05). Significantly increased values for apoproteins B (P <0.05), Cifi (P <0.001), and E (P <0.005) were observed in all diabetic patients relative to their respective controls. No statistical significance was observed, for ape CU concentrations, between diabetic patients and their non-diabetic controls, nor between diabetic groups. However, the type 2 patient group had a significantly lower ape CII to triglyceride ratio than that of the type 1 patients. , in the present study we selected only diabetic males because, at least within our diabetic population, they constituted a more stable group with regard to treatment adherence and the degree of glycemic control. All diabetics selected had comparable values for glycated hemoglobin, which allowed comparisonsbetween type 1 and type 2 patients. The BMI of our type 2 patients was greater than that of type 1 patients; reflecting the known close association between type 2 diabetes and obesity (20 3,4, 7) ; near normal values in our type 2i patients together with its elevation in type 1 patients would suggest that the original peripheral insulin resistance in diabetic subjects is a causative factor in determining low HDL cholesterol concentrations in untreated diabetics.
Plasma
In all our diabetic groups, plasma ape B concentrations were higher than in the controls. This factor may be important, because the risk of coronary heart disease with increased ape B, independent of its associated cholesterol, has been documented (21). Of further note was that the apoprotein Al to B ratio in the type 1 group was no different from its control group (1.30 ± 0.25 vs 1.32 ± 0.20) , whereas in the type 2 groups the Al:B ratios were significantly lower than in controls (type 2d, 0.92 ± 0.30, and type 2i, 0.94 ± 0.25, vs 1.26 ± 0.23 in the control group; P <0.001). Such ratios for assessing coronary heart disease risk under other circumstances must, in diabetics, be used cautiously.
In all diabetic groups, concentrations of apolipoproteins Cifi and E in plasma exceeded control values. These apoproteins, together with ape B, are known to constitute the greater apeprotein proportion of the VLDL and IDL fractions (22), so these findings would suggest an accumulation of these particles in plasma. This is further evidenced by the increased IDL cholesterol concentrations we observed. Such ape E-enriched particles (synonomously termed "remnant") were shown by Fielding et al. (23) to be associated with a marked decrease in cholesterol effiux from fibroblasts that had been cultured in plasma from patients with type 2 diabetes. Such a finding is consistent with cholesteryl ester accumulation in cells and possible atherosclerotic sequelae. An explanation of the phenomenon of remnant accumulation in diabetes is not immediately apparent. A possible explanation could be the inhibitory effect of ape CIII on the lipase-mediated catabolism of lipeprotems (24). However, in all our diabetic patients, plasma triglyceride, VLDL cholesterol, and VLDL triglyceride concentrations were unremarkable and, moreover, because the concentrations of the lipase activator, ape CII (25), were similar to those of the control subjects, this would suggest no striking abnormalities in the enzyme's function of catabolism of the triglyceride-rich VLDL. Indeed, the finding that the insulin-treated type 1 patients have a significantly higher CII to triglyceride ratio (data not shown) suggests an enhancement of extrahepatic lipeprotein lipase activity (26); hepatic lipase activity, remaining unaffectedor decreased (27) , may result in the accumulation, in plasma, of the triglyceride-depleted "remnant" particles that we have observed.
In conclusion, our results indicate that in the overall clinical and laboratory management of diabetes, it may not suffice, in relation to premature cardiovascular risk, to aim for a "normalization" of total plasma cholesterol and (or) triglyceride concentrations.
One should also address the question of the distribution of lipeprotein subfractions and apoproteins in plasma.
